Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Britannia Life Sciences Inc Com C.RLSC

RISE Life Science Corp is engaged in developing and evolving medical and adult hemp-based formulations to create general use of health and well-being products for the emerging consumer category. It derives key revenue from the United States.


CSE:RLSC - Post by User

Comment by GianniM1on Nov 24, 2015 5:25pm
172 Views
Post# 24321640

RE:RE:RE:RE:RE:RE:RE:Positive thoughts

RE:RE:RE:RE:RE:RE:RE:Positive thoughts

I think most paniced about the "Strategic Review"... and with good raeson, especially when a pre-revenue company announces it..

BUT

it just seems to me now (from the lack of updates re: milestones updates at this point in the year) that they had many items on their objectives for this year, and not enough $$$ to carry them... not because they are not telling us something or the technology is a dud....  more of a time issue (and buying more time) with the approvals.  (and maybe new/more costs thant originally planned with some of the processes)

It's like they had $3 (all borrowed of course) and basically $10 worth of ideas....
good in the long run and for the future of the company...but bad for the short term and if you cant deliver all of them as initially planned....

So when they recap their 2015 report card, they will hit some, and miss others, basically attributing to lack of funds (hence the "stratgic review")

So more cost cutting (IR department comes to mind...lol)... and more than likely workplace prescreening and retail sales taking the cut (for now) and staying on track for the big ticket CFDA and FDA....or trying to sell the IP....

the good news, is that they secured financing (extended the terms) so that will bring in confidence again..and like others mentioned, the lenders are seeing something good in all this.....and so they will get to follow through with some of their objectives.

also good news for those that picked more shares at these bargain prices.... 




Donlin wrote:
Great to see MOM back at 2.5 cents.  I would like to take this as a positive but time will tell.


Bullboard Posts